Skye Bioscience, Inc. (SKYE)
| Market Cap | 7.25M-87.6% |
| Revenue (ttm) | n/a |
| Net Income | n/a-19.2% |
| EPS | n/a-19.8% |
| Shares Out | 4.39M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 55,683 |
| Open | 1.69 |
| Previous Close | 1.62 |
| Day's Range | 1.62 - 1.75 |
| 52-Week Range | 1.50 - 14.08 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 12.00(+627.27%) |
| Earnings Date | n/a |
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
About SKYE
Skye Bioscience, Inc., a clinical-stage biotechnology company, develops molecules that modulate G-protein-coupled receptors to treat obesity, overweight, and related metabolic diseases. The company's lead clinical asset is nimacimab, a peripherally-restricted negative allosteric modulating antibody targeting cannabinoid receptor 1 (CB1) administered as a subcutaneous injectable, which targets CB1 receptors in peripheral tissues including adipose, liver, and muscle tissues with limited central nervous system accumulation. Nimacimab addresses metabolic processes related to energy expenditure, fat mobilization, leptin sensitivity, appetite regulation, and satiety signaling. Skye Bioscience, Inc. was formerly known as Emerald Bioscience Inc. and changed its name to Skye Bioscience, Inc. in December 2020. Skye Bioscience, Inc. was incorporated in 2011 and is based in San Diego, California.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$SKYE stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in SKYE holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by SKYE's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
SKYE Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New SKYE patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to SKYE from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in SKYE
| ETF | Est. Holding Size |
|---|---|
| VTIVanguard Morningstar Total Stock Market ETF | $117.98K |
| VXFVanguard Extended Market ETF | $38.84K |
Estimated from each fund’s disclosed top holdings × AUM
SKYE Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from SKYE’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score